News -CureApp, Inc.

　CureApp, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake, hereafter, “the Company”) entered into a license agreement with Sawai Group Holdings Co., Ltd. (Head Office: Yodogawa-ku, Osaka; Representative Director and President: Kazuhiko Sueyoshi, hereafter, “the Sawai Group”) for the development and marketing of a DTx solution (hereafter, “the app”) in the NASH (Non-Alcoholic Steatohepatitis) field. 　With the conclusion of this agreement, the Sawai Group obtains exclusive rights concerning the development and marketing of the app indicated for the treatment of NASH. 　Under this agreement, the Company is set to receive up to 10.5 billion yen in total in the form of a lump sum contractual payment, and as additional payments for milestones reached based on future clinical development progress and sales targets. After launch, the Company plans to introduce the app at medical institutions via its proprietary app prescription service (APS). *1 Abbreviation of Digital Therapeutics. Softwa

  Strategic growth investment in CureApp to support the rollout of its hypertension app and advance its new development pipeline, as digital therapeutics gain traction in Japan Tokyo, Japan, August 16, 2022 – Global investment firm Carlyle (NASDAQ:CG) today announced a strategic partnership with CureApp, Inc., a leading Japanese medical technology (“MedTech”) company and prescription digital therapeutics provider, through an acquisition of a significant minority stake in the company. The investment is part of CureApp’s Series G funding, whereby Carlyle will be investing JPY 7 billion in the company. This brings the total amount of capital raised by CureApp to approximately JPY 13.4 billion. Carlyle will have one board seat as part of the transaction. Founded in 2014 by two physicians, CureApp is one of Japan’s fastest-growing MedTech companies specializing in the research and development of prescription and non-prescription digital therapeutics. Its hypertension prescription digital